Amarin -5% after FDA delays ANCHOR SPA appeal, MKM downgrades


Amarin (AMRN -5%) is downgraded to Neutral from Buy at MKM Partners after it announced the FDA had delayed making a determination on the company's request to reinstate the ANCHOR clinical trial Special Protocol Assessment agreement.

MKM continues to expect AMRN to have a difficult time significantly growing Vascepa prescriptions in the face of a smaller sales force and new ACC/AHA lipid guidelines that essentially only recommend statins for lipid management, and the firm does not expect AMRN to secure a near-term partnership for the drug.

From other sites
Comments (2)
  • johnsonstarfish
    , contributor
    Comments (98) | Send Message
     
    Guess who wants cheap shares?
    16 Jan 2014, 06:37 PM Reply Like
  • Teddie
    , contributor
    Comments (194) | Send Message
     
    Not I -- wouldn't touch this thing.
    17 Jan 2014, 04:31 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs